Screener
Cogent Biosciences, Inc. COGT Income Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $70.81M+13.8% | $75.37M+19.6% | $75.56M+21.8% | $68.99M+8.4% | $62.2M+14.6% | ||
| $31.83M+138% | $28.24M+137% | $23.93M+105% | $14.37M+21.7% | $13.38M+32.6% | ||
| $102.64M+35.8% | $103.61M+38.3% | $99.49M+34.9% | $83.36M+10.5% | $75.58M+17.4% | ||
| -$102.64M-35.8% | -$103.61M-38.3% | -$99.49M-34.9% | -$83.36M-10.5% | -$75.58M-17.4% | ||
| $1.22M+288% | $1.21M— | $1.29M— | $1.46M— | $314K— | ||
| $6.23M+204% | $6.26M+112% | —— | $2.43M-49.3% | $2.05M-62.2% | ||
| -$96.41M-31.1% | -$97.35M-35.2% | -$102.49M-50.9% | -$80.93M-14.6% | -$73.53M-24.7% | ||
| -$0.52+1.9% | -$0.53-1.9% | -$0.61-22.0% | -$0.50+3.8% | -$0.53-23.3% | ||
| -$101.9M-36.0% | -$102.98M-38.6% | -$98.85M-35.2% | -$82.71M-10.6% | -$74.93M-17.5% | ||
| -$102.64M-35.8% | -$103.61M-38.3% | -$99.49M-34.9% | -$83.36M-10.5% | -$75.58M-17.4% |
FAQ
- Is Cogent Biosciences, Inc. profitable?
- Cogent Biosciences, Inc. is not currently profitable: it reported a net loss of $377.2M over the trailing twelve months, a -950.4% net margin.
- What is Cogent Biosciences, Inc.'s earnings per share?
- Cogent Biosciences, Inc.'s diluted EPS over the trailing twelve months is $-2.16.
- Where does Cogent Biosciences, Inc.'s income statement data come from?
- Every line is extracted from Cogent Biosciences, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.